anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Small cell lung cancer (SCLC) is a highly lethal malignancy that is not treatable with targeted therapies and that does not respond long-term to treatment with cytotoxic chemotherapy1. One distinguishing molecular characteristic of SCLC is very high expression levels of thymidylate synthase (TS). TS plays an important role in de novo nucleotide biosynthesis and the very high TS levels expressed in SCLC cells indicate that these cells require the de novo nucleotide biosynthetic pathway to proliferate. Thus, complete TS inhibition could result in highly favorable outcomes in SCLC patients. TS inhibitors have been evaluated in SCLC clinical trials and have anti-tumoral activity when combined with a second chemotherapeutic agent. However, treatment with TS inhibitors has not been shown to surpass other combination chemotherapy regimens. An important point regarding these clinical studies is that TS activity levels were not monitored as an endpoint of drug response, thus it is not known whether TS activity was efficiently inhibited.Investigators predict that complete TS inhibition will result in favorable outcomes.

With support from Wake Innovations, Investigators are developing a novel fluoropyrimidine polymer, CF10, which strongly inhibits TS. CF10 is a second generation fluoropyrimidine polymer. The first generation polymer, F10, showed excellent anti-cancer activity in animal models of acute myeloid leukemia, glioblastoma, and prostate cancer. CF10 is designed to have improved tumor penetration and better in vivo stability than F10. Investigators hypothesize that CF10 will be highly effective for treating SCLC both as a single agent and in combination with TS inhibitors that target alternative sites of the TS enzyme.

After establishing CF10 has activity as a single agent and in combination with folate-based TS inhibitors (e.g. pemetrexed) in SCLC cell lines and xenograft models, Investigators will test CF10 in patient-derived xenograft (PDX) models and in organoids derived from SCLC patient samples. Investigators will develop PDX models of SCLC and SCLC organoids using transbronchial fine needle aspiration (FNA) from SCLC patients at Baptist/WFBCCC collected by co-I's Bellinger, Dotson, and Thomas. Non-malignant cells will be collected using a brush biopsy to enable comparison of malignant and non-malignant tissue from the same patient with regard to mechanistic endpoints.
Participants will have not experienced infection (positive test) - we will aim to recruit both vaccinated and unvaccinated individuals although the latter may be harder to recruit. They will identify as of Caucasian ethnicity. Uninfected subjects, will be recruited by advertisement within KCL or social media, from non-COVID in-patients or outpatients or attending A\&E at GSTT and at SARS-CoV2 antigen testing centres and vaccination centres and at PIC sites.
To minimize periprosthetic joint infection (PJI) risk, some clinicians prescribe extended antibiotic prophylaxis (EAP) following total joint arthroplasty (TJA). Given the limited evidence supporting EAP, we sought to evaluate impact of prophylactic antibiotic duration on PJI risk in a murine TJA model. A titanium prosthesis was implanted into the proximal tibia of 89 mice and inoculated with 102 colony forming units (cfu) of Staphylococcus aureus Xen36. Control mice (n = 20) did not receive antibiotics. Treated mice received either 24 h (n = 35) or 4 days (n = 34) of cefazolin prophylaxis. Cultures were obtained from the prostheses, tibia, femur, and knee tissues 3 weeks after surgery. All mice in the control group developed PJI. Both prophylaxis regimens reduced the rate of PJI relative to the control, with only 2/35 mice in the 24-h cohort (p < 0.0001) and 1/34 in 4-day cohort developing PJI (p < 0.0001). CFU counts from the prostheses, bone and knee tissues were reduced for the 24-h and 4-day prophylaxis cohorts relative to the control (p < 0.0001 for both). There was no difference in rates of PJI or CFU counts between the two prophylaxis cohorts (p = 0.58). Prophylactic cefazolin profoundly reduced rates of PJI in a murine model of TJA in which all control animals developed PJI. Extending cefazolin prophylaxis duration from 24 h to 4 days did not result in improved PJI rates or decreased bacterial loads in infected cases. While these results strongly support use of antibiotic prophylaxis for TJA, EAP did not appear to add benefit in the described mouse model.
Natural interspecies antibodies (Ab) can be assigned to different animal species (e.g.mammals and birds) and have restricted reaction with a cellular antigen inherent to all animals and birds under conditions of cellular stress. Very high levels of Ab may indicate a tumour. Ab present initially destroy some tumours cell, causing release of Ag ('reaction pattern in vertebrate cell antigens') which induce the immune system to produce more Ab. This corresponds to slow tumour growth and a good prognosis. USE/ADVANTAGE - Ab can be used in human or veterinary medicine for (1) preventing a pre-existing organ pattern; (2) for healing or preventing diseases associated with cell proliferation; (3) for diagnosing diseases of uncontrolled cell proliferation; or (4) for prepn. of highly purified, natural interspecies antigens (Ag) from solns. of biological materials. All mammals and birds produce functionally indistinguishable Ab.
Pulmonary arterial hypertension (PAH) is a complicating factor in the management of congenital heart disease (CHD) with intracardiac or extracardiac communications. In children with moderate to severe PAH, the risk of serious complications following the surgical repair of shunts (including right cardiac failure and death) is 15-20% or even higher, and the risk of late, postoperative residual PAH is \~25%. We therefore intend to conduct a study aimed at reducing the risk of severe immediate postoperative complications and the risk of residual PAH at six months following surgery to less than 10% in children with moderate PAH (primary objective). The study is also aimed at promoting a statistically significant reduction in pulmonary artery pressure and pulmonary vascular resistance at six month after surgery, compared with baseline in children with moderate or severe PAH (secondary objective). We hypothesized that these goals could be achieved by treating patients preoperatively and for six months postoperatively with sildenafil, either singly or combined with bosentan. Both drugs have been approved for treatment of PAH on the basis of randomized clinical trials. Preoperative and postoperative (on treatment) hemodynamic evaluation will be based on noninvasive and invasive diagnostic procedures. As an additional objective, we intend to analyze possible abnormalities in genes that have been shown to be associated with PAH-CHD, and inflammatory mediators as well. The idea is to investigate whether changes in these markers correlate with the clinical profile and response to treatments.
We plan to enroll 10 subjects with relapsing MS. All enrolled subjects will receive Ofatumumab 20 mg every 4 weeks, subcutaneously for 9 months during the study. Loading doses will be administered initially at 1, 7 and 14 days. During the study period, all enrolled subjects will undergo five PET scans using \[F-18\] PBR06 at 0, 5, 28, 90 and 273 days after starting treatment with Ofatumumab.
The invention relate to a kind of lactoferrin application method in food, long time eat the food with lactoferrin that is good for healthy, improve the immunity ability, suit to population. The invention comprise the procedure as follow; the lactofewin dissolve with the solvent, then add into food ingredient to mix homogeneous or add into food ingredient directly to mix home generous, the food include diary produce, milk powder, candy, drinking, oral liquid, tablet, electuary, capsule, the solvent is water or liquid food material. The mixed food ingredient pass through above 90DEG C high temperature disinfection, then cold down. The lactoferrin is encapsulation lactoferrin or capsulation lactofrrin. The add quantity of lactoerrin is 3.0mg-10mg every 100g ingredient. The contain quantity is above 3.0mg every 100mg.
Risk Summary

Published literature reports that breast feeding after intravenous iohexol administration to the mother would result in the infant receiving an oral dose of approximately 0.7% of the maternal intravenous dose; however, lactation studies have not been conducted with oral, intrathecal, or intracavity administration of iohexol. There is no information on the effects of the drug on the breastfed infant or on milk production. Iodinated contrast agents are excreted unchanged in human milk in very low amounts with poor absorption from the gastrointestinal tract of a breastfed infant. Exposure to iohexol to a breastfed infant can be minimized by temporary discontinuation of breastfeeding (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for OMNIPAQUE and any potential adverse effects on the breastfed infant from OMNIPAQUE or from the underlying maternal condition.

Clinical Considerations

Interruption of breastfeeding after exposure to iodinated contrast agents is not necessary because the potential exposure of the breastfed infant to iodine is small. However, a lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for 10 hours (approximately 5 elimination half-lives) after OMNIPAQUE administration to minimize drug exposure to a breastfed infant.
PURPOSE:To provide a pharmaceutical composition containing activated vitamin D having improved dispersibility and solubility and excellent thermal stability, by using activated vitamin D and a stright-chain saturated fatty acid propylene glycol ester as essential components. CONSTITUTION:The objective composition can be produced by dissolving an activated vitamin D (e.g. 1alpha-hydroxycholecalciferol) in a propylene glycol ester of a 6-14C straight-chain saturated fatty acid. The amount of the straight-chain saturated fatty acid propylene glycol ester is 10,000-10,000,000pts.wt. per 1pt.wt. of the acivated vitamin D. The fatty acid constituting the stright-chain saturated fatty acid propylene glycol ester is preferably 6C caproic acid, 10C capric acid, etc., and the ester is preferably a diester.
PROBLEM TO BE SOLVED: To obtain the subject composition to be used between treatments in the therapy of dental caries, excellent in cavity filling ability, easy to remove, and useful as an interim dental filler free from any clinically uncomfortable feeling such as pain due to chilled water or bite. SOLUTION: This resin-based sealing material composition is obtained by incorporating resin-based composition comprising a liquid composed of a radical- polymerizable monomer, a plasticizer (e.g. dimethyl phthalate) and a polymerization initiator and powder composed of filler powder (e.g. polyethyl methacrylate) and the polymerization initiator with rosin or sandarac (pine resin). It is preferable that the amounts of the rosin or sandarac, the plasticizer and the polymerization initiator to be used are 1-40 pts.wt., 20-120 pts.wt. and 0.1-5 pts.wt., based on 100 pts.wt. of the radical-polymerizable monomer, respectively.
An encapsulated ascorbic acid composition is a formulation that protects the encapsulated ascorbic acid from unwanted interactions and significantly reduces the likelihood of an unwanted allergic reaction for many users. The encapsulated ascorbic acid composition accomplishes this through the use of sunflower lecithin. Sunflower lecithin is utilized as carrier material that forms the liposomal barrier surrounding a quantity of the ascorbic acid. Sunflower lecithin does not contain common allergens, allowing for increased accessibility of the encapsulated ascorbic acid composition. Additionally, the sunflower lecithin contains a higher quantity of the phospholipid, phosphatidylcholine, compared to other lecithin sources. Phosphatidylcholine is readily absorbed increasing the bioavailability of ascorbic acid in a user. Furthermore, high quantities of phosphatidylcholine form smaller, more stable, and more uniformly shaped liposome resulting in better absorption.
Inspiratory Muscle Training (IMT) intensity was set at 15% PImax. The walking program consisted of walking every day at an intensity of "somewhat hard" to "hard" on the Borg's Rating of Perceived Exertion (RPE) scale. Participants were encouraged to walk at 10 to 15 minutes, once to twice a day initially, then progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate.
Breast cancers (BCs) are solid tumors composed of heterogeneous tissues consisting of cancer cells and an ever-changing tumor microenvironment (TME). The TME includes, among other non-cancer cell types, immune cells influencing the immune context of cancer tissues. In particular, the cross talk of immune cells and their interactions with cancer cells dramatically influence BC dissemination, immunoediting, and the outcomes of cancer therapies. Tumor-infiltrating lymphocytes (TILs), tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) represent prominent immune cell populations of breast TMEs, and they have important roles in cancer immunoescape and dissemination. Therefore, in this article we review the features of TILs, TAMs, and MDSCs in BCs. Moreover, we highlight the mechanisms by which these immune cells remodel the immune TME and lead to breast cancer metastasis.
Proanthocyanidins (PAs) are an important group of flavonoids that contribute to astringency, color, and flavor in grapes (Vitis vinifera) and wines. They also play a crucial role in enhancing plant resistance to various stresses. However, the underlying regulatory mechanism governing PAs biosynthesis, particularly in relation to conferring resistance to powdery mildew, has not been extensively explored. This study focused on identifying a key player in PAs biosynthesis, namely the plant U-box (PUB) E3 ubiquitin ligase VvPUB26. We discovered that overexpression of VvPUB26 in grapes leads to a significant increase in PAs content, whereas interfering with VvPUB26 has the opposite effect. Additionally, our findings demonstrated that overexpression of VvPUB26 in transgenic grapevines enhances defense against powdery mildew while interfering with VvPUB26 results in increased susceptibility to the pathogen. Interestingly, we observed that VvPUB26 interacts with the WRKY transcription factor VvWRKY24, thereby facilitating ubiquitination and degradation processes. Through RNA-Seq analysis, we found that VvWRKY24 primarily participates in secondary metabolites biosynthesis, metabolic pathways, and plant-pathogen interaction. Notably, VvWRKY24 directly interacts with the promoters of dihydroflavonol-4-reductase (DFR) and leucoanthocyanidin reductase (LAR) to inhibit PAs biosynthesis. Meanwhile, VvWRKY24 also influences the expression of MYB transcription factor genes related to PAs synthesis. In conclusion, our results unveil a regulatory module involving VvPUB26-VvWRKY24-VvDFR/VvLAR that plays a fundamental role in governing PAs biosynthesis in grapevines. These findings enhance our understanding of the relationship between PAs biosynthesis and defense mechanisms against powdery mildew.
The present invention discloses a urine sugar and blood sugar lowering capsule with rhizoma polygonati and folium panacis japonici cum caule, which belongs to the class of Chinese herbal medicinal preparations. Diabetes is a common endocrine disease, and the cause of the disease is relevant to the splanchnic dysfunction of a human body. Patients whose states of diseases are not well controlled usually have complications of the eye, the heart, the kidney the peripheral vessel and the nerve, which brings huge harm to individuals and families. In the prior art, methods for curing diabetes mainly depend on medicines to control the state of diseases, but can not treat both the manifestation and the root cause of diseases, and patients with complications are more difficult to cure. According to the six evils and the seven modes of emotions, and according to the principle that diseases are cured by finding out the causes of the diseases through the symptom of the causes of diseases, the capsule of the present invention is prepared from rhizoma polygonati, folium panacis japonici cum caule, semen sesami and other Chinese herbal medicines through scientific processing. After the capsule is taken, the capsule can lower urine sugar and blood sugar, obviously regulate the functions of a human body, directly revive the endocrine system, and forcefully enhance the immunological function. When frequently taken, the capsule can obviously improve and restore the blood sugar of a patient. The medicine develops a new way for curing diabetes.
The invention relates to a medicine for preventing and treating infantile influenza. A medicine for preventing and treating infantile influenza A is characterized in that: the monarch drug is composed of crude drugs of wormwood, magnolia officinalis, fructus forsythiae and sweet wormwood, and the ministerial drug is composed of radix trichosanthis, scutellaria baicalensis, notopterygium root, radix angelicae pubescentis and radix sileris. Rhizoma Polygonati, Ginseng radix, flos Rosae chinensis, cortex Lycii, pericarpium Trichosanthis, and radix Angelicae Dahuricae are used as adjuvant drugs. Fructus Aurantii, pericarpium Citri Tangerinae, cyclocarya paliurus and Glycyrrhrizae radix are used as guiding drugs. A method for preparing a medicine for preventing and treating infantile influenza A comprises proportionally collecting raw materials, cleaning, sieving, mixing, and packaging into non-woven bag; or mixing the whole body at a certain proportion, and packaging into medicated bath bag. The invention has scientific and reasonable formula, brings out the best in the effects of the medicines, has rich raw material resources, simple and feasible preparation method, easy production and preparation, convenient and quick use and obvious curative effect, is an innovation on the medicines for preventing and treating the infantile influenza A and has good economic and social benefits.
<P>PROBLEM TO BE SOLVED: To provide more effective anti-HCV (Hepatitis C Virus) treatment.  <P>SOLUTION: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in the patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Palbociclib was assessed for carcinogenicity in a 6-month transgenic mouse study and in a 2-year rat study. Oral administration of palbociclib for 2 years resulted in an increased incidence of microglial cell tumors in the central nervous system of male rats at a dose of 30 mg/kg/day (approximately 8 times the human clinical exposure based on AUC). There were no neoplastic findings in female rats at doses up to 200 mg/kg/day (approximately 5 times the human clinical exposure based on AUC). Oral administration of palbociclib to male and female rasH2 transgenic mice for 6 months did not result in increased incidence of neoplasms at doses up to 60 mg/kg/day. 

Palbociclib was aneugenic in Chinese Hamster Ovary cells in vitro and in the bone marrow of male rats at doses ≥100 mg/kg/day for 3 weeks. Palbociclib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay and was not clastogenic in the in vitro human lymphocyte chromosome aberration assay.

In a fertility study in female rats, palbociclib did not affect mating or fertility at any dose up to 300 mg/kg/day (approximately 4 times human clinical exposure based on AUC) and no adverse effects were observed in the female reproductive tissues in repeat-dose toxicity studies up to 300 mg/kg/day in the rat and 3 mg/kg/day in the dog (approximately 6 times and similar to human exposure [AUC], at the recommended dose, respectively).

The adverse effects of palbociclib on male reproductive function and fertility were observed in the repeat-dose toxicology studies in rats and dogs and a male fertility study in rats. In repeat-dose toxicology studies, palbociclib-related findings in the testis, epididymis, prostate, and seminal vesicle at ≥30 mg/kg/day in rats and ≥0.2 mg/kg/day in dogs included decreased organ weight, atrophy or degeneration, hypospermia, intratubular cellular debris, and decreased secretion. Partial reversibility of male reproductive organ effects was observed in the rat and dog following a 4- and 12-week non-dosing period, respectively. These doses in rats and dogs resulted in approximately ≥10 and 0.1 times, respectively, the exposure [AUC] in humans at the recommended dose. In the fertility and early embryonic development study in male rats, palbociclib caused no effects on mating but resulted in a slight decrease in fertility in association with lower sperm motility and density at 100 mg/kg/day with projected exposure levels [AUC] of 20 times the exposure in humans at the recommended dose.
Clinical studies of diltiazem did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Information for Patients

30 mg – Diltiazem hydrochloride tablets, USP may be swallowed whole, crushed, or chewed. Do not split diltiazem hydrochloride tablets, USP.

60 mg, 90 mg, and 120 mg – Diltiazem hydrochloride tablets, USP may be swallowed whole, crushed, or chewed.
Each participant will complete a baseline study day. For 7 days prior to the study day each participant will eat a controlled diet of 1g protein/kg body weight/day.